SAI is reduced by the muscarinic acetylcholine antagonist scopolamine [24], enhanced by acetylcholinesterase inhibitors [25] and is altered in clinical populations featuring loss of acetylcholine-producing cells, such as Alzheimer’s disease [26–28], mild cognitive impairment [26,29] and Parkinson’s disease with mild cognitive impairment [30]. Here, ACHE is linked to Cognitive impairment.